CLDN6 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Read More

Pharma Industry News

Could Context Therapeutics’ CLDN6 T cell engager strategy gain traction after ovarian cancer results?

Find out how Context Therapeutics’ CTIM-76 ovarian cancer data could shape its CLDN6 T cell engager strategy and investor outlook.

bySoujanya Ravi

June 20, 2026

web analytics